Home > Gastroenterology > LAUNCH: TACE plus lenvatinib efficacious in advanced HCC

LAUNCH: TACE plus lenvatinib efficacious in advanced HCC

Presented By
Prof. Ming Kuang, Sun Yat-sen University, China

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GI 2022
Trial
Phase 3, LAUNCH
Lenvatinib plus transarterial chemoembolisation (TACE) may represent a novel frontline therapy for patients with advanced hepatocellular carcinoma (HCC). The phase 3 LAUNCH trial demonstrated the superiority of this combination regimen over lenvatinib monotherapy, with an acceptable safety profile [1]. Prof. Ming Kuang (Sun Yat-sen University, China) explained that TACE reduces tumour burden swiftly in patients with advanced HCC but with potential post-treatment neovascularisation and subsequent tumour recurrence and metastasis. Lenvatinib inhibits angiogenesis and tumour cell proliferation. Therefore, Prof. Kuang argued that the assessment of a TACE plus lenvatinib combination in advanced HCC is reasonable. The multicentre, phase 3 LAUNCH trial (NCT03905967) rando...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on